Hemagen Diagnostics, Inc. (HMGN) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.36: the stock has moved about 64% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHemagen Diagnostics, Inc. (HMGN) trades at $0.0002. Hemagen Diagnostics, Inc. develops and markets clinical diagnostic solutions for human and veterinary applications. The company focuses on immunoassays for autoimmune and infectious diseases, selling directly and through distributors. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for HMGN: HMGN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Hemagen Diagnostics, Inc. (HMGN) Healthcare & Pipeline Overview
Hemagen Diagnostics, Inc. is a biotechnology company specializing in human and veterinary clinical diagnostic solutions, primarily immunoassays for autoimmune and infectious diseases. With a focus on direct and distributor sales, Hemagen serves laboratories, hospitals, and blood banks globally, operating in the competitive diagnostic market.
What Is the Investment Thesis for HMGN?
Hemagen Diagnostics, Inc. presents a focused investment opportunity within the biotechnology sector, specifically in the clinical diagnostics market. The company's specialization in immunoassays for autoimmune and infectious diseases provides a degree of market niche. A key value driver is the potential for increased adoption of its VIRGO line and specialty assays. However, potential investors may want to evaluate the company's negative profit margin of -22.4% and the competitive landscape. Growth catalysts include expanding distribution networks and developing new diagnostic assays. The company's beta of 0.36 suggests lower volatility compared to the broader market. The absence of a dividend may deter some investors seeking income.
Based on FMP financials and quantitative analysis
HMGN Key Highlights
Hemagen Diagnostics, Inc. operates with a relatively small team of 15 employees, indicating a lean operational structure.
- The company's gross margin stands at 39.9%, reflecting its ability to manage production costs effectively.
- Hemagen Diagnostics, Inc. has a beta of 0.36, suggesting lower volatility compared to the overall market.
- The company's profit margin is -22.4%, indicating current challenges in achieving profitability.
- Hemagen Diagnostics does not currently offer a dividend, which may influence investor interest.
Who Are HMGN's Competitors?
HMGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HMGN's Key Strengths?
Specialized expertise in immunoassays.
- Established VIRGO product line.
- Direct sales and distribution network.
- Proprietary assays and technologies.
What Are HMGN's Weaknesses?
Negative profit margin.
- Limited scale compared to larger competitors.
- Dependence on a relatively small number of products.
- OTC market listing may limit investor access.
What Are the Key Risks for HMGN?
Financial-distress signal — its Altman Z-Score of -14.16 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Increased competition from larger diagnostic companies with greater resources.
- Regulatory changes affecting diagnostic testing and approval processes.
- Patent expirations on key products, leading to generic competition.
- Negative profit margin indicating financial challenges.
What Are HMGN's Competitive Advantages?
- Specialized expertise in immunoassays for autoimmune and infectious diseases.
- Established VIRGO product line with a recognized brand in the diagnostics market.
- Direct sales and distribution network providing access to key customer segments.
- Proprietary assays and technologies offering differentiation from competitors.
What Does HMGN Do?
Founded in 1985 and based in Columbia, Maryland, Hemagen Diagnostics, Inc. is a biotechnology company providing clinical diagnostic solutions for human and veterinary applications. The company's core business revolves around the development, manufacture, and marketing of diagnostic products, with a primary focus on immunoassays. Its VIRGO line of immunoassays is used for the diagnosis of autoimmune and infectious diseases, as well as acute phase proteins. Hemagen's human diagnostics product line includes Universal IFA components, supplies, controls, calibrators, accessories, H-rotors, reagents, electrodes, equipment, and specialty assays for conditions like Chagas disease, acute phase proteins, and cytokines. In addition to its human diagnostics offerings, Hemagen provides a range of veterinary diagnostic products. These include equipment, reagents, supplies, accessories, and electrodes used in chemistry, hematology, and electrolyte analysis. The company distributes its products through a combination of direct sales and a network of distributors, serving a diverse customer base that includes laboratories, hospitals, and blood banks worldwide. Hemagen's market position is characterized by its specialized focus on niche diagnostic areas and its established presence in both the human and veterinary clinical diagnostics markets.
What Products and Services Does HMGN Offer?
- Develops and manufactures human clinical diagnostic products.
- Offers immunoassays for diagnosing autoimmune and infectious diseases.
- Provides veterinary diagnostic products for animal health.
- Markets the VIRGO line of immunoassays.
- Sells products directly to laboratories, hospitals, and blood banks.
- Distributes products through a network of distributors worldwide.
- Offers specialty assays for conditions like Chagas disease.
How Does HMGN Make Money?
- Develops and manufactures diagnostic assays and related products.
- Sells diagnostic products directly to end-users, such as laboratories and hospitals.
- Distributes products through a network of distributors to expand market reach.
- Generates revenue from the sale of reagents, equipment, and accessories.
What Industry Does HMGN Operate In?
Hemagen Diagnostics, Inc. operates within the biotechnology industry, specifically in the clinical diagnostics segment. This segment is characterized by continuous innovation, driven by the need for more accurate and efficient diagnostic tools. The market is competitive, with established players and emerging companies vying for market share. Key trends include the increasing adoption of immunoassay-based diagnostics and the growing demand for veterinary diagnostic solutions. Hemagen's focus on specialized assays positions it within a niche market, but it faces competition from larger diagnostic companies like BSYI, DRWN, EMDF, FFNTF, and GSAC.
Who Are HMGN's Key Customers?
- Clinical laboratories
- Blood banks
- Veterinary clinics and hospitals
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Hemagen Diagnostics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Columbia, US. The company is led by CEO William Hales. HMGN has traded publicly since 1993.
Key Financial Metrics
Return on equity for Hemagen Diagnostics, Inc. stands at 29.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -37.1%, showing how much profit it generates from its asset base. A current ratio of 1.07 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Hemagen Diagnostics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.16 places it in the distress zone, a signal of elevated financial risk.
HMGN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
HMGN Latest News
No recent news available for HMGN.
HMGN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HMGN.
Price Targets
Wall Street price target analysis for HMGN.
HMGN MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HMGN; grades run from A+ (80-100) to F (below 30).
Leadership: William Hales
CEO
William Hales serves as the CEO of Hemagen Diagnostics, Inc. His leadership is pivotal in guiding the company's strategic direction and overseeing its operations in the biotechnology and clinical diagnostics sectors. With a focus on innovation and market expansion, Hales is responsible for driving the development and commercialization of Hemagen's diagnostic solutions.
Track Record: As CEO, William Hales manages a team of 15 employees and is responsible for the overall performance of Hemagen Diagnostics, Inc. Key achievements under his leadership include maintaining the company's position in the diagnostics market and overseeing the development of new assays. His strategic decisions focus on expanding the company's product portfolio and distribution network.
HMGN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hemagen Diagnostics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, which increases the risk for investors. Trading on the OTC Other tier differs significantly from trading on major exchanges like the NYSE or NASDAQ, where companies are subject to stricter listing standards and regulations.
- OTC Tier: OTC Other
- Limited financial disclosure increases investment risk.
- Lower trading volume and liquidity can lead to price volatility.
- OTC listing indicates potential financial or operational challenges.
- Regulatory oversight is less stringent compared to major exchanges.
- Potential for fraud or manipulation is higher on the OTC market.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's capital structure and debt levels.
- Check for any pending lawsuits or investigations.
- Consult with a qualified financial advisor.
- Company has been in business since 1985.
- Focus on specialized diagnostic solutions.
- Direct sales and distribution network.
- Established VIRGO product line.
HMGN Healthcare Stock FAQ
What do analysts say about HMGN stock?
As of March 17, 2026, there is no readily available analyst coverage for Hemagen Diagnostics, Inc. (HMGN) due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and consider the risks associated with investing in OTC stocks.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- Financial data is limited.